Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

This publication has 36 references indexed in Scilit:

• Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients
  Diabetes Care, 2008
• Effects of Torcetrapib in Patients at High Risk for Coronary Events
  New England Journal of Medicine, 2007
• Clinical update: adverse effects of antiretroviral therapy
  The Lancet, 2007
• Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults
  American Journal of Physiology-Endocrinology and Metabolism, 2007
• Class of Antiretroviral Drugs and the Risk of Myocardial Infarction
  New England Journal of Medicine, 2007
• The use of the Framingham equation to predict myocardial infarctions in HIV‐infected patients: comparison with observed events in the D:A:D Study
  HIV Medicine, 2006
• Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone
  HIV Medicine, 2005
• Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
  New England Journal of Medicine, 2005
• Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized Trial
  JAMA, 2004
• Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
  AIDS, 2003